Where Will Eli Lilly Be in 10 Years?
Eli Lilly (NYSE: LLY) is executing very well right now, and Wall Street is aware of that. The stock's price-to-earnings (P/E) ratio of 50 is below its five-year average of 54, but very high on an absolute basis. For reference, the S&P 500 index has a P/E ratio of 28.5. Before you buy shares in Lilly, think about what might happen over the next decade.
The big story around Eli Lilly is the success of its GLP-1 drugs Mounjaro (for diabetes) and Zepbound (for weight loss). They are currently leading the market for this type of medication. The impact on the company's business is significant, with Mounjaro's sales rising 109% year over year in the third quarter of 2025. Zepbound performed even better, with sales increasing by 185%.
Image source: Getty Images.
Source Fool.com
